AU2008203277B2 - Peptide vaccines against group A streptococci - Google Patents

Abstract

This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies andlor anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. This invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines. -+ ~CD Number of Isolate tQ20.7 % emm"""""""" ,. .J 00D 08.3 % emm2 C1 4.1% emm4 0 3.7% emm8' CD 2.8% emm77/271 CD C-CD 2.5% emm2 CD 2.2% emm4 1.8% emm3 1.7% emm5 1.6% emm2 1.5% emm1 1.2% emm5

Description

AUSTRALIA Patents Act 1990 COMPLETE SPECIFICATION Standard Patent Applicant(s): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION, TECHNOLOGY TRANSFER OFFICE Invention Title: PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCI The following statement is a full description of this invention, including the best method for performing it known to me/us: P51243.AU. I PalSotFl-ing Applicatown 2008-7-23 doc (M) loz PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCI 5 CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 60/291,835, filed May 18, 2001. 10 FIELD OF THE INVENTION This invention relates generally to immunoreactive molecules, compositions, and methods related thereto. Specifically, those related to Group A Streptococci. More specifically, it relates to synthetic Group A strep immunoreactive peptides, 15 compositions comprising the peptide sequences, vaccines, isolated antibodies elicited by the peptides, kits comprising the peptides or antibodies, and methods of using the peptides, compositions, vaccines and antibodies. BACKGROUND OF THE INVENTION 20 Group A streptococci (GAS) are responsible for a wide variety of diseases. These range from uncomplicated pharyngitis to more serious invasive diseases such as necrotizing fasciitis ("flesh eating syndrome") and streptococcal toxic shock syndrome. Additionally, approximately 3% of GAS infections that go untreated will result in acute 25 rheumatic fever. (Brandt, E. R., Good, M. F. 1999. Vaccine strategies to prevent rheumatic fever. Immunol. Res. 19:89-103) All ages are susceptible to GAS attack, but those particularly vulnerable are the elderly, children under 2 years, and African Americans. (Emerging Infections Programs (EIP), supported by the National Center for Infectious Diseases for isolates resulting from active surveillance 1995-1997. 30 California EIP: Arthur Reingold; Connecticut EIP: Matt Carter; Georgia EIP, Monica Farley; Minnesota EIP, Kristine MacDonald; Oregon EIP, Paul Cieslak; Centers for Disease Control and Prevention (CDC), K. O'Brien, B. Beall, K. Deaver-Robinson, R. Facklam, A. Kraus, A. Schuchat, B. Schwartz) Recently, there has been a significant increase in the number of streptococcal infections (Davies, H. D., McGeer, A., 35 Schwartz, B., et al. 1996. Invasive group A streptococcal infections in Ontario, Canada. Ontario group A streptococcal study group. N. Engl. J. Med. 335:547-54) as well as 2 rheumatic fever (Veasey, L. G., Wiedneier, S. W., Osmond, G. S., et al. Resurgence of acute rheumatic fever in the intermountain region of the United States. N. Engl. J. Med. 316:42-7). Based on recent active surveillance, it is estimated that there are approximately 8,500 cases and 1,300 deaths annually in the United States from 5 invasive GAS disease, (EIP supported by the National Center for Infectious Diseases for isolates resulting from active surveillance 1995-1997. California EIP: Arthur Reingold; Connecticut EIP: Matt Carter; Georgia EIP, Monica Farley; Minnesota EIP, Kristine MacDonald; Oregon EIP, Paul Cieslak; CDC, K. O'Brien, B. Beall, K. Deaver-Robinson, R. Facklam, A. Kraus, A. Schuchat, B. Schwartz). 10 A vaccine against GAS could eliminate millions of dollars in health care costs and numerous physician visits. There are a number of strategies that have been used towards designing an 15 effective streptococcal vaccine (Salvadori, L. G., Blake, M. S., McCarty, M., Tai, J. Y., Zabriskie, J. B. 1995. Group A streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capabilities of the antibodies. J. Infect. Dis. 171:593-600; Ji, Y. Carlson, B., Kondagunta, A., Cleary, P. P. 1997. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by 20 group A streptococcus. Infect. Immun. 65:2080-2087; Kapur, V. Maffei, J. T., Greer R. S., Li, L. L., Adams, G. J., Musser, J. M. 1994. Vaccination with streptococcal cysteine protease protects mice against challenge with heterologous group A streptococci. Microb. Pathogenesis. 16:443-450; Dale, J. B., Baird, R. W., Courtney, H. S., Hasty, D. L., Bronze, M. S. 1994. Passive protection of mice against group A streptococcal 25 pharyngeal infection by lipoteichoic acid. J. Infect. Dis. 169:319-323; Dale, J. B., Washburn, R. G., Marques, M. B., Wessels, M. R. 1996. Hyuaronated capsule and surface M protein in resistance to opsonization of group A streptococci. Infect. Immun. 64:1495-1501; Fischetti, V. A. 1989. Streptococcal M protein: molecular design and biological behavior. Clin. Microbiol. 2:285-314; Lancefield, R. C. 1962. Current 30 knowledge of the type-specific M antigens of group A streptococci. J. Immun. 89:307 313; Lancefield, R. C. 1959. Persistence of type-specific antibodies in man following infection with group A streptococci. J. Exp. Med. 110:271-283). There are difficulties associated with a vaccine strategy involving the M 35 protein, such as the large number of serologic M (emm) types (over 100 serotypes) and the observation that some M proteins contain epitopes that cross-react with human -3 tissues. In addition to the large number of serotypes, every population has a different subset of GAS serotypes which are the most prevalent. In order to deal with these difficulties, different approaches have been tried. For example, observation that the M protein's C-terminus is conserved while the N-terminus is variable has led some 5 workers to try to focus on the C-terminus for broader protection and others to focus on the N-terminus where the most variability is. Even though some M protein-based vaccines have been designed, for the above reasons, a need still exists for a flexible, effective, multivalent GAS vaccine. 10 SUMMARY OF THE INVENTION A first aspect provides a composition comprising at least one polypeptide comprising the amino acid sequence according to any one of SEQ ID NOs:1, 3 and 14, 15 wherein the polypeptide is capable of eliciting an immune response to a serotype of Group A Streptococcus (GAS) and does not elicit tissue cross-reactive antibodies. A second aspect provides an immunogenic composition for eliciting a protective immune response to Group A Streptococcus comprising an immunogenic amount of 20 the composition according to the first aspect. A third aspect provides a method for inducing an immune response against multiple serotypes of Group A Streptococcus comprising administering an immunogenic amount of the immunogenic composition of the first aspect to a subject. 25 A fourth aspect provides an isolated polypeptide comprising the amino acid sequence according to any one of SEQ ID NOs:1, 3 and 14 wherein the polypeptide is capable of eliciting an immune response to a serotype of GAS and does not elicit tissue cross-reactive antibodies. 30 Additional aspects of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The aspects of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended 35 claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. 2621679_1 (GHMatters) P51243.AU.1 2/05/11 -4 BRIEF DESCRIPTION OF THE DRAWINGS The accompanying drawing, which is incorporated in and constitutes a part of 5 this specification, illustrates several aspects of the invention and together with the description, serves to explain the principles of the invention. Figure 1 shows a bar graph of a population-based U.S. sterile site invasive isolate distribution among the 24 most prevalent emm types (2321 (88.9%) of the 10 entire 2612 isolate sample) of Group A strep. The 10 most prevalent isolates (emm1, emm3, emm28, emm12, emm4, emm1 1, emm89, st2967, emm77/27L, emm6) account for 65% of the disease. DESCRIPTION OF THE PREFERRED EMBODIMENTS 15 Before the present compounds, compositions, articles, devices, and/or methods are disclosed and described, it is to be understood that this invention is not limited to specific peptides, specific synthetic methods, specific compositions, specific vaccines, specific antibodies, specific kits, specific methods of use, as such may, of course, vary. 26216791 (GHMatters) P51243AU.1 2/05/11 5 It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. It must be noted that, as used in the specification and the appended claims, the 5 singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a peptide" includes mixtures of peptides, reference to "a carrier" includes mixtures of two or more carriers, and the like. Ranges may be expressed herein as from "about" one particular value, and/or to 10 "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to 15 the other endpoint, and independently of the other endpoint. In this specification and in the claims which follow, reference will be made to a number of terms which shall be defined to have the following meanings: 20 The terms "peptide", "polypeptide" and "protein" are used interchangeably and as used herein refer to more than one amino acid joined by a peptide bond. "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where 25 said event or circumstance occurs and instances where it does not. By the term "effective amount" of a compound as provided herein is meant a nontoxic but sufficient amount of the compound to provide the desired biological effect. As will be pointed out below, the exact amount required will vary from subject 30 to subject, depending on the species, age, and general condition of the subject, the particular compound used, its mode of administration, and the like. Thus, it is not possible to specify an exact "effective amount." However, an appropriate effective amount may be determined by one of ordinary skill in the art using only routine experimentation. 35 -6 By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained. 5 "Synthetic" is meant to encompass items, e.g., peptides, which are not naturally occurring, in that they are isolated, synthesized, or otherwise manipulated by man. "Immunoreactive" as used herein is meant to encompass materials which are 10 capable of reacting with a specific antigen. "Antigenic" and "immunogenic" are terms which fall within the scope of the term "immunoreactive". "Composition" as used throughout the specification and claims is meant to include any composition of matter, including the peptides, polypeptides, proteins, 15 mixtures, vaccines, antibodies or other forms of matter. It is meant to be used generically and interchangeably with the other composition of matter terms, and if used in addition to the other terms, it is used for sake of completeness. "Composition" is a broad term overlapping the coverage of these more specific terms and when used in addition to these more specific terms it is not meant as an indication that it is 20 necessarily different from these more specific terms. The present disclosure provides synthetic peptides, compositions, and a vaccine made therefrom and isolated antibodies elicited by administration thereof. The disclosure also provides methods for using the peptides, compositions, vaccines, or 25 antibodies such as, vaccination of recipients. The disclosure further provides a method for tailoring vaccines. The disclosure additionally provides kits for using the peptides or antibodies. Peptides 30 Disclosure herein are synthetic peptides of approximately 20-25 amino acids in length selected from a section of approximately 45 amino acids from the most N terminal region of the M proteins of the most prevalent U.S. Group A Streptococcus (GAS) serotypes which are immunoreactive. At least some of the peptides are capable of eliciting opsonic antibodies and/or anti-attachment antibodies to the GAS serotypes 35 without eliciting tissue cross-reactive antibodies. The synthetic peptides may be from the most prevalent invasive U.S. GAS serotypes which are immunoreactive. The prevalence data in Figure 1 includes data from invasive isolates. The most frequently 26216791 (GHMatlers) P51243.AU.1 2105/11 -7 occurring invasive types reflect the incidence rate of the same types found in non invasive isolates. Specific peptides of the present disclosure are shown below in Table 1. These include a peptide consisting essentially of the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, 5 SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ED NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID 10 NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID 15 NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID 20 NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO: 103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID 25 NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID 30 NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, or SEQ ID NO:138. Examples of the peptides of the present disclosure, several for each of the 25 most common serotypes (138 peptides), are as follows: 26216791 (GHMatters) P51243.AU.1 2/05/11 8 TABLE 1. Synthesized Type-Specific Peptides. Seq ID Peptide No: Serotype designation Peptide 1 Mi Mi-i CNGDGNPREVIEDLAANNPAIQ 2 M1-2 CIQNIRLRHENKDLKARLENA 3 M1-3 CIRLRHENKDLKARLENAMEV 4 MI-4 CNGDGNPREVIEDLAANNPAME 5 MI-5 CIERNIRLRHENKDLKARLENA 6 M1-6 CNGDGNPREVIEDLAANNPVIQ 7 M1-7 CNGDGNPRVVIEDLAANNPAIQ 8 M1-8 CIRLRHHENKDLKARLENAMEV 9 M2 M2-1 CNSKNPVPVKKEAKLSEAELHDK 10 M2-2 CKKEAKLSEAELHDKIKNLEEEK 11 M2-3 CELHDKIKNLEEEKAELFEKLD 12 M2-4 CELFEKLDKVEEEHKKVEEEHKK 13 M3 M3-1 CDARSVNGEFPRHVKLKNEIE 14 M3-2 CGEFPRHVKLKNEIENLLDQV 15 M3-3 CLDQVTQLYTKHNSNYQQYNA 16 M3-4 CLDQVTQLYNKHNSNYQQYSA 17 M3-5 CLDQVTQLYTKHNSNYQQYSA 18 M3-6 CLNQVTQLYTKHNSNYQQYNA 19 M3-7 CLAQVTQLYTKHNSNYQQYNA 20 M3-8 CLNQVTQLHTKHNSNYQQYNA 21 M3-9 CRSDARSVNGEFPRHVKLKNE 22 M3-10 CQLYTKHIYTKHNSNYQQYNAQ 23 M3-11 CTQLYTKHNSNYQQYNAQAGR 24 M4 M4-1 CAEIKKPQADSAWNWPKEYNA 25 M4-2 CDSAWNWPKEYNALLKENEEL 26 M4-3 CKENEELKVEREKYLSYADDK 27 M4-4 CEELKVEREKYLSYADDKEKDPQ 9 Seq ID Peptide No: Serotype designation Peptide 28 Ml1 M1 1-1 CAGQSAPKGTNVSADLYNSLWDE 29 M11-2 CKGTNVSADLYNSLWDENKT 30 M1 1-3 CDENKTLREKQEEYITKIQNE 31 M1 1-4 CTEVKAAGQSAPKGTNVSADL 32 M12 M12-1 CDHSDLVAEKQRLEDLGQKFE 33 M12-2 CAEKQRLEDLGQKFERLKQRS 34 M12-3 CLEDLGQKFERLKQRSELYLQ 35 M12-4 CKFERLKQRSELYLHQYYDNK 36 M12-5 CKFERLKRRSELYLQQYYDNK 37 M12-6 CKQRSELYLQQYYDNKSNRYK 38 M12-7 CSELYLQQYYDNKSNGYKGDW 39 M22 M22-1 CESSNNAESSNISQESKLINT 40 M22-2 CESSNISQESKLINTLTDENEK 41 M22-3 CESKLINTLTDENEKLREELQQ 42 M22-4 CNTLNTLTDENEKLREELQQ 43 M22-5 CESSNISQESKLINTLTIDENEK 44 M22-6 CEKLREELQQYYALSDAKEEE 45 M28 M28-1 CAESPKSTETSANGADKLAD 46 M28-2 CKSTETSANGADKLADAYNTL 47 M28-3 CDKLADAYNTLLTEHEKLRDE 48 M28-4 CTEHEKLRDEYYTLIDAKLEEK 49 M28-5 CTEHEKLRDEYYTLIDAKEEE 50 M77 M77-1 CEGVSVGSDASLHNRITDLEEEREK 51 M77-2 CSDASLHNRITDLEEEREKLLNK 52 M77-3 CDLEEEREKLLNKLDKVEEEHKKD 53 M77-4 CDLEEERGKLLNKLDKVEEEHK 54 M77-5 CLNKLDKVEEEHKKDHEQLEK 10 Seq ID Peptide No: Serotype designation Peptide 55 M89 M89-1 CDSDNINRSVSVKDNEKELHNK 56 M89-2 CDNINRSVSVKDNEKELHNKIAD 57 M89-3 CSVKDNEKELHNKIADLEEER 58 M89-4 CELHNEIADLEEERGEHLDKID 59 M89-5 CELHNKIADLEEERGAHLDKID 60 M89-6 CDSDNINRFVSVKDNEKELHN 61 M89-7 CDSDNSDNINRSVSVKDNEKE 62 M89-8 CLEEERGEHLDKIDELKEELK 63 st2967 st2967-1 CNSKNPAPAPASAVPVKKEATK 64 st2967-2 CVPVKKEATKLSEAELYNKIQ 65 st2967-3 CKKEATKLSEAELYNKIQELEE 66 st2967-4 CNSKNPAPAPAVPVKKEATKL 67 st2967-5 CNSKNPAPAVPVKKEATKLSE 68 st2967-6 CAELYNKIQELEEGKAELFDK 69 M6 M6-1 CRVFPRGTVENPDKARELLNK 70 M6-2 CRGTVENPDKARELLNKYDVEN 71 M6-3 CENPDKARELLNKYDVENSMLQ 72 M6-4 CENSMLQANNDNLTDQNKNLTD 73 M6-5 CNSMLQANNDKL'TENKNLTD 74 M82 M82-1 CDSSSRDlTEAGVSKFWKSKFD 75 M82-2 CRD1TEAGVSKFWKSKFDAEQN 76 M82-3 CEAGVSKFWKSKFDAEQNRANE 77 M82-4 C DAEQNRANELEKKLSGYEKD 78 M43 M43-1 CEEHPDVVAARESVLNNVR 79 M43-2 CHPDVVAARESVLNNVRVPGT 80 M43-3 CRVPGTLWLRQKEENDKLKLEK 81 M43-4 CLRQKEENDKLKLEKKGLETE 11 Seq ID Peptide No: Serotype designation Peptide 82 M75 M75-1 CEEERTFTELPYEARYKAWKSE 83 M75-2 CELPYEARYKAWKSENDELREN 84 M75-3 CNDELRENYRRTLDKFNTEQ 85 M75-4 CKAWKSENDELRENYRKTLDK 86 M75-5 CRENYRRTLDKFNTEQGKTITR 87 M33 M33-1 CEEHEKVTQAREAVIREMQQR 88 M33-2 CHEKVTQAREAVIREMQQRGT 89 M33-3 CEMQQRGTNFGPLLASTMRDNH 90 M92 M92-1 CDDRSVSTNSGSVSTPYNNLLNE 91 M92-2 CRSVSTNSGSVSTPYNNLLNE 92 M92-3 CEYDDLLAKHGELLSEYDALK 93 M92-4 CDLLAKHGELLSEYDALKEKQDK 94 M5 M5-1 CTVTRGTINDPQRAKEALDKYE 95 M5-2 CDPQRAKEALDKYELENHDLK 96 M5-3 CENHDLKTKNEGLKTENEGLK 97 MS-4 CQRAKAALDKYELENHDLKTKN 98 M5-5 CTVTRGTVNDPQRAKEALDKYE 99 MS-6 CTVTRGTVNDPQRAKETLDKYE 100 M5-7 CTVTRGTINDPQRAKEVIDKYE 101 M5-8 CTVTRSTINDPQRAKEALDKYE 102 M5-9 CHDLKTKNEGLKTENEGLKTEN 103 M94 M94-1 CEEASNNGQLTLQHKNNALTSE (fonnerly emml3W) 104 M94-2 CQHKNNALTSENESLRREKDR 105 M94-3 CESLRREKDRYLYEKEELEKK 106 M94-4 CRREEKDRYLYEKEELEKKNK 12 Seq ID Peptide No: Serotype designation Peptide 107 M73 M73-1 CDNQSPAPVKKEAKKLNEAE 108 M73-2 CKKEAKKLNEAELYNKIQELE 109 M73-3 CELYNKIQELEEGKAELFDKLEK 110 M73-4 CDNQSPALVKKEAKKLNEAEL 111 M73-5 CDNQSPAPAPVKKEAKKLNEAE 112 M73-6 CQELEEGKAELFDKLEKVEEE 113 M18 M18-1 CAAPLTRATADNKDELIKRAND 114 M18-2 CRATADNKDELIKRANDYEIQ 115 M18-3 CEIQNHQLTVENKKLKTDKEQ 116 M18-4 CRATADNKDELIKRANGYEIQ 117 M18-5 CKDELIKRKELTUEIQNHQL 118 M18-6 CNHQLTVENKKLKTDKEQLTKE 119 M58 M58-1 CDSSREVTNELTASMWKAQAD 120 M58-2 CREVTNELTASMWKAQADSAK 121 M58-3 CKAKELEKQVEEYKKNYETLEK 122 M58-4 CDSSREVTNELAASMWKAQAD 123 M58-5 CDSSRDSSREVTNELTASMWK 124 M58-6 CKAKELEKQVEEYKKNYETLEK 125 M59 M59-1 CEQAKNNNGELTLQQKYDALT 126 M59-2 CELTLQQKYDALTNENKSLRRE 127 M59-3 CNENKSLRRERDNYLNYLYEK 128 M59-4 CRRERDNYLNYLYEKEELEKK 129 M101 M101-1 CADHPSYTAAKDEVLSKFSVPGH (formerly stNS5) 130 M101-2 CKDEVLSKFSVPGHVWAHERE 131 M101-3 CHEREKNDKLSSENEGLK 132 M101-4 CDKLRLEKEELKTDLQKKERE 133 M101-5 CKNDKLSSENEGLKAGLQEKE - 13 Seq ID Peptide No: Serotype designation Peptide 134 M41 M41-1 CEGNARLAQAQEEALRDVLNN 135 M41-2 CRLAQAQEEALRDVLNNTPHN 136 M41-3 CQAQEEALRDVLNNTPHNQLRD 137 M41-4 CDVLNNTPHNQLRDAYAGAFRR 138 M41-5 CQLRDPYAGAFRRNNELEKIIQE It is important to note that a single peptide representing each of the 25 M serotypes represented is predicted to protect against the majority of invasive GAS within each of these serotypes in the U.S. For the majority of these types, the present 5 disclosure provides a peptide that actually matches the sequences of all GAS of these types that we have encountered. We include additional peptides that encompass the extent of M protein gene allelic variation that we have encountered to date within each type from various geographic locations. It is important to note that for the majority of these types, at least one peptide is conserved among all allelic variants that we have 10 encountered. The small size of the peptides disclosed herein allows a flexible approach for formulating compositions or vaccines. The formulations can be readily and inexpensively changed to account for changes in GAS serotype frequencies in the 15 target population. The adaptability includes frequency changes between populations, years, and the like. Any population for which there is frequency data can have a vaccine formulation customized for it by the methods disclosed herein, which are discussed below. 20 Recently a rapid M protein gene-based subtyping system has been initiated which predicts the type-specific portion of the M protein with very high efficiency. (Beall, B., Facklam, R., Hoenes, T., Schwartz, B. 1997. A survey of emm gene sequences from systemic Streptococcus pyogenes infection isolates collected in San Francisco, CA; Atlanta, GA; and Connecticut state in 1994 and 1995. J. Clin. Microbiol. 25 35:1231-1235; Beall, B., Facklam, R., Elliot, J., Franklin, A., Hoenes, T., Jackson, D., Laclaire, L., Thompson, T., Viswanathan, R. 1998. Streptococcal emm types associated with T-agglutination types and the use of conserved emm restriction fragment patterns for subtyping group A Streptococci. J. Med. Micro. 47:1-6). A Centers for Disease Control and Prevention (CDC) surveillance system used this rapid 30 gene based M subtyping system to gather epidemiological data which showed that the 26216791 (GHMatters) P51243AU.1 2/05/11 -14 30 most prevalent invasive serotypes account for approximately 95% of the total invasive isolates in the U.S. In addition, these peptides should have direct use in formulating vaccines for 5 countries other than the U.S. For example, the 25 serotypes represented in Table 1 also appear to encompass the majority of GAS pediatric pharyngitis isolates in Rome, Italy (91/114=80%), 85% (367/430) of a mixture of sterile and non-sterile GAS isolates recovered in Mexican patients, and 80% (110/137) of primarily invasive isolates recently recovered from patients in Argentina. 10 It is also important to note that data indicates that these 25 serotypes would have less coverage in other geographic areas such as Malaysia, India, New Guinea, Nepal, and Egypt. For example, out of 136 pharyngitis and impetigo isolates recently recovered in Egypt, only 62 (46%) were of one of these 25 types. While type emm1 is 15 by far the most prevalent type recovered from invasive and non-invasive U.S. isolates (about 20%), only 5/136 (4%) Egypt isolates were type emm1. Thus, the methods of the present disclosure could be used to tailor vaccines or compositions with the serotypes most prevalent in these areas. 20 The peptides are synthesized by any of the techniques known in the art, as the method of making them is not critical. One technique is through recombinant methods. Another is manual or automated chemical synthesis using individual amino acids, such as solid phase peptide synthesis. Other methods for synthesizing peptides may be readily apparent to one of ordinary skill in the art. 25 One of ordinary skill in the art would be able to determine through routine experimentation which of the immunoreactive peptides are capable of eliciting opsonic and/or anti-attachment antibodies. 30 Though it is known generally in the art that even single substitutions may have a great impact on immunogenicity of a molecule, due to allelic variants which exist for any particular GAS serotype, there are expected to be allowable substitutions within the peptides corresponding with each serotype which maintain immunogenicity. As discussed above, the example peptides in Table 1 include allelic variants of the 35 peptides for a given serotype. For example, up to approximately 3 substitutions within each peptide which correspond with variants of a given serotype may create peptides which also are immunoreactive. That a given substitution results in an immunoreactive 26216791 (GHMatters) P51243.AU.1 2/05/11 - 15 peptide can be determined by routine experimentation by making a proposed substitution then testing the immunoreactivity by one of many known assays including those described herein. A variant within a serotype can be identified on the basis of sequence. Any variation within 50 N-terminal residues of mature protein of M protein 5 gene type strain is considered a variant. Isolates within an emm type share about 284% deduced amino acid sequence identity [as determined by the Wisconsin Package Version 10.1, Genetics Computer Group (GCG), Madison Wisc. FASTA program] within the mature amino terminal 45 amino acids compared to the reference type strain sequence. The first three peptides indicated for each serotype in Table 1 10 are considered to be the peptides from the majority of isolates of the serotype. The additional peptides given in Table 1 for each serotype in some instances represent the majority of isolates in the type, and in other instances represent known variants of these types. 15 At least some of the individual peptides are capable of protecting a recipient against its corresponding serotype. A composition comprising a mixture of peptides from more than one serotype is able to protect against those corresponding serotypes. A mixture can be tailored such that it contains the most prevalent serotypes in an area (population), thus making the mixture able to protect against the most important 20 serotypes. The tailoring is accomplished by matching the serotype-specific peptides to epidemiological data regarding the prevalence of the serotypes for the population of recipients desired to be protected. Though each peptide will be immunoreactive for the serotype upon which it is 25 based, the peptides of the present disclosure may even provide non-serotype-specific effects. It is believed that it is possible that certain prevalent N-terminal fragments may evoke cross-protective opsonic antibodies. This is demonstrated in Example 5 below. It is expected that the present peptides, compositions or vaccines will evoke cross-type opsonization. 30 Compositions. Vaccines, and Kits Also disclosed herein are polypeptides, proteins, compositions, or vaccines comprising the disclosed peptides or sequences of the peptides. The peptides, in addition to being used individually, can be used as a mixture of peptides. One specific 35 embodiment is a composition comprising the peptides of the present disclosure as described above. A composition comprising a mixture of peptides is readily prepared by methods well known in the art. Alternatively, to using the peptides individually or in a 26216791 (GHMatters) P51243 AU.1 2105/11 - 16 mixture, the peptides may be joined together into a polypeptide or protein. Another specific embodiment is a polypeptide comprising the sequences of peptides of the present disclosure. Another specific embodiment is a protein comprising the sequences of the peptides of the present disclosure. Standard techniques known in the 5 art may be used to, for example, link the synthesized peptides, synthesize a polypeptide or protein which contains segments corresponding to the desired synthetic peptides, or link the synthetic peptides to a backbone or a liposome. Examples of backbones include, for example, keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, diphtheria toxoid, bacterial outer membrane proteins, and artificial 10 amino acid backbones. It is well known to one of ordinary skill in the art how to covalently bond peptides to a backbone or liposome or how to create polypeptides or proteins using recombinant techniques. As noted above, a vaccine comprising these synthetic peptides is within the 15 scope of the present disclosure. The vaccine may comprise an immunogenic amount of the peptide immunogens. The data from a CDC surveillance system showing the epidemiological data, as noted above, showed that the 30 most prevalent invasive M types account for approximately 95% of the total invasive isolates in the U.S. An aspect of the present disclosure is the development of a multi-antigenic peptide (MAP) 20 vaccine representing these most prevalent serotypes. The peptides of the present disclosure may be conveniently formulated into vaccine compositions comprising one or more of the peptides alone or in association with a pharmaceutically acceptable carrier. See, e.g., Remington's Pharmaceutical Sciences, latest edition, by E.W. Martin Mack Pub. Co., Easton, PA, which discloses typical carriers and conventional methods 25 of preparing pharmaceutical compositions that may be used in conjunction with the preparation of formulations of the disclosed peptides and which is incorporated by reference herein. A benefit of the vaccine is it can eliminate over 85% of Group A Streptococci infections and reduce by 85% the nasopharyngeal reservoir of Group A Streptococci in the United States with the correct tailoring. The reservoir of GAS is 30 expected to be reduced for the population, not just an individual. Reduction in GAS would have an effect on carriage of the organism, thereby affecting the reservoir in the population. Reduction in carriage of the organism subsequently reduces the exposure rate, thereby increasing herd immunity. 35 The vaccine comprises and can be made by providing immunogenic amounts of the peptides alone or in a pharmaceutically acceptable vehicle or carrier. Carriers include water, saline, dextrose, and glycerol, for example. The vaccine can further comprise 2621679_1 (GHMatters) P51243.AU.1 2105/11 -17 additional immune-stimulatory molecules, including other GAS immunogens, vaccines of other species (such as H. influenza, pertussis, N. meningitidis, pneumococcus, or Influenzae), and adjuvants or mixture of adjuvants. One of ordinary skill in the art would be able to identify appropriate vehicles, carriers, other antigens or immunogens, 5 and immunomodulators, such as adjuvants or cytokines. Additional additives would also be readily apparent to one of skill in the art, such as wetting agents or preservatives. A DNA vaccine is also within the scope of the present disclosure. Specifically 10 disclosed is a DNA vaccine comprising DNA encoding immunoreactive peptides or compositions of the present disclosure. Methods for making DNA sequences suitable for DNA vaccines are known in the art. One of ordinary skill would be able to determine appropriate promoters or other regulatory sequences which may be used in the DNA construct encoding the immunoreactive compositions. DNA vaccines may further 15 comprise other components as in the vaccines and compositions described above and below, such as carriers and agents which increase levels of immunity, such as liposomes. DNA vaccines may be administered by routes similar to other vaccines. Administration of a DNA vaccine results in expression of antigens which produce a protective immune response. 20 Though the vaccine of the present disclosure is expected be most effective with multiple serotype-specific peptides, it could contain from one serotype-specific peptide to multiple serotype-specific peptides for every identified serotype of GAS. One of skill in the art would be able to determine the most cost-effective and clinically therapeutic 25 combination based on epidemiological data, using the tailoring method provided herein. Specifically disclosed is a vaccine containing at least 3 serotype-specific peptides from 3 different serotypes. For example, a vaccine comprising serotype specific peptides for emm1, emm3, and emml2 is expected to protect against approximately 38% of invasive GAS disease in the U.S. More specifically, this vaccine 30 can comprise the following peptide combinations from Table 1: 26216791 (GHMatters) P51243.AU.1 2/05/11 18 Mi-i MI-2 Ml-3 M1-4 Mi-5 M1-6 Ml-7 M1-8 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 Mi-I M1-2 M1-3 M1-4 M1-5 MI-6 M1-7 M1-8 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 Mi-i MI-2 M1-3 MI-4 M1-5 M1-6 M1-7 M1-8 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 Mi-i M1-2 M1-3 M1-4 M1-5 M1-6 MI-7 Mi-8 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 Mi-i MI-2 M1-3 M1-4 MI-5 M1-6 M1-7 Mi-8 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 Mi-i M1-2 MI-3 Mi-4 M1-5 M1-6 Mi-7 M1-8 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 Mi-1 M1-2 Mi-3 M1-4 M1-5 Mi-6 M1-7 Mi-8 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 Mi-i MI-2 M1-3 M1-4 M1-5 M1-6 M1-7 M1-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 Mi-i M1-2 M1-3 M1-4 M1-5 M1-6 MI-7 MI-8 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 Mi-i M1-2 M1-3 M1-4 MI-5 MI-6 MI-7 Mi-8 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 Mi-i M1-2 MI-3 M1-4 MI-5 M1-6 M1-7 Mi-8 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 M12-1 Mi-i M1-2 MI-3 M1-4 Mi-5 MI-6 MI-7 M1-8 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 Mi-i MI-2 M1-3 M1-4 MI-5 MI-6 M1-7 MI-8 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 Mi-i MI-2 Mi-3 M1-4 Mi-5 Mi-6 M1-7 Mi-8 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 Mi-i M1-2 MI-3 M1-4 M1-5 M1-6 MI-7 Mi-8 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 Mi-I M1-2 M1-3 M1-4 Mi-5 M1-6 M1-7 MI-8 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 19 Mi-i M1-2 M1-3 Mi-4 M1-5 Ml-6 M1-7 M1-8 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 MI-I MI-2 M1-3 M1-4 Mi-5 M1-6 M1-7 Mi-8 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 MI-I M1-2 Mi-3 Mi-4 MI-5 MI-6 MI-7 Mi-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M12-2 M12-2 M12-2 M12-2 M12-1 M12-2 M12-2 M12-2 Mi-i M1-2 MI-3 Mi-4 M1-5 M1-6 M1-7 Mi-8 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 Mi-i M1-2 M1-3 MI-4 Ml-5 M1-6 MI-7 M1-8 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 Mi-i Mi-2 M1-3 MI-4 MI-5 M1-6 M1-7 M1-8 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 M12-2 Mi-i Mi-2 MI-3 Mi-4 Mi-5 M1-6 MI-7 Mi-8 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 Mi-i MI-2 M1-3 M1-4 Mi-5 MI-6 Ml-7 Mi-8 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 MI-i MI-2 MI-3 Mi-4 MI-5 M1-6 M1-7 MI-8 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 Mi-i M1-2 MI-3 M1-4 Mi-5 MI-6 M1-7 Mi-8 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 MI-1 M1-2 Mi-3 M1-4 M1-5 M1-6 M1-7 MI-8 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 Mi-i Mi-2 MI-3 M1-4 Mi-5 MI-6 M1-7 Mi-8 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 Mi-I Mi-2 MI-3 M1-4 M1-5 M1-6 M1-7 Mi-8 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 Mi-i MI-2 MI-3 Mi-4 Mi-S M1-6 M1-7 M1-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 Mi-i Ml-2 MI-3 Mi-4 Mi-5 M1-6 MI-7 Mi-8 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 Mi-i Mi-2 Ml-3 M1-4 Mi-5 M1-6 M1-7 MI-8 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 20 Mi-I Ml-2 M1-3 MI-4 Mi-5 M1-6 MI-7 Mi-8 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 M12-3 Mi-I M1-2 M1-3 MI-4 M1-5 M1-6 M1-7 M1-8 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 Mi-I M1-2 MI-3 M1-4 M1-5 M1-6 M1-7 M1-8 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 Mi-i M1-2 MI-3 M1-4 Mi-5 M1-6 M1-7 Mi-8 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 Mi-I M1-2 M1-3 M1-4 M1-5 M1-6 M1-7 Mi-8 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 Mi-i M1-2 M1-3 M1-4 Mi-5 M1-6 M1-7 Mi-8 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 MI-i M1-2 MI-3 MI-4 Mi-5 MI-6 M1-7 M1-8 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 Mi-i M1-2 M1-3 M1-4 Mi-5 MI-6 MI-7 Mi-8 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7- M3-7 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 MI-i MI-2 MI-3 MI-4 MI-5 M1-6 MI-7 Mi-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M12-4 M12-4 M12-4 M12-4 M12-1 M12-4 M12-4 M12-4 Mi-i Mi-2 M1-3 MI-4 M1-5 M1-6 M1-7 M1-8 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 Mi-i M1-2 M1-3 M1-4 MI-5 Mi-6 MI-7 M1-8 M3-1O M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 Mi-i M1-2 MI-3 M1-4 Mi-5 M1-6 MI-7 Mi-8 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 M12-4 Mi-i M1-2 M1-3 MI-4 M1-5 MI-6 M1-7 MI-8 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 Mi-i M1-2 MI-3 M1-4 M1-5 M1-6 M1-7 Mi-8 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 Mi-i MI-2 M1-3 M1-4 MI-5 M1-6 MI-7 MI-8 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 Mi-I M1-2 M1-3 M1-4 M1-5 M1-6 MI-7 MI-8 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M34 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 21 Mi-i M1-2 Mi-3 M1-4 M1-5 M1-6 M1-7 M1-8 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 Mi-i M1-2 Mi-3 M1-4 M1-5 M1-6 Mi-7 M1-8 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 Mi-i MI-2 MI-3 Mi-4 M1-5 M1-6 MI-7 MI-8 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 Mi-i M1-2 MI-3 M1-4 M1-5 Mi-6 M1-7 M1-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 MI-i M1-2 M1-3 M1-4 M1-5 Mi-6 MI-7 MI-8 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 Mi-i MI-2 MI-3 MI-4 Mi-5 MI-6 MI-7 Mi-8 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 Mi-i MI-2 MI-3 Mi-4 Mi-5 MI-6 M1-7 M1-8 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 M12-5 MI-i M1-2 M1-3 Mi-4 Mi-5 M1-6 Mi-7 Mi-8 M3-1 M3-i M3-1 M3-1 M3-1 M3-i M3-1 M3-1 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 Mi-i MI-2 MI-3 MI-4 M1-5 MI-6 M1-7 Mi-8 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 Mi-i M1-2 Mi-3 M1-4 Mi-5 Mi-6 MI-7 MI-8 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 MI-i MI-2 MI-3 M1-4 MI-5 MI-6 Mi-7 M1-8 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 Mi-i Mi-2 Ml-3 MI-4 M1-5 M1-6 Mi-7 Mi-8 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M12-6 -M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 Mi-i M1-2 M1-3 M1-4 M1-5 M1-6 Mi-7 Mi-8 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 MI-i Mi-2 Mi-3 Mi-4 MI-5 MI-6 Mi-7 MI-8 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 MI-i MI-2 MI-3 M1-4 M1-5 M1-6 MI-7 M1-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M12-6 M12-6 M12-6 M12-6 M12-1 M12-6 M12-6 M12-6 MI-i M1-2 Mi-3 Mi-4 M1-5 M1-6 Mi-7 Mi-8 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 -22 M1-1 M1-2 M1-3 MI-4 MI-5 M1-6 M1-7 MI-8 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M1-1 MI-2 M1-3 MI-4 MI-5 M1-6 M1-7 M1-8 M3-11 M3-M3- 13-1 M3-11 M3-11 M3-i1 M3-11 M3-11 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 M12-6 Mi-1 MI-2 M1-3 MI-4 MI-5 MI-6 M1-7 M1-8 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 Mi-1 M1-2 MI-3 MI-4 MI-5 MI-6 M1-7 MI-8 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M1-1 M1-2 M1-3 MI-4 MI-5 MI-6 M1-7 MI-8 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 Mi-1 MI-2 MI-3 M1-4 M1-5 MI-6 M1-7 M1-8 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M1-1 MI-2 M1-3 MI-4 MI-5 M1-6 M1-7 M1-8 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M1-1 MI-2 MI-3 MI-4 M1-5 M1-6 M1-7 Mi-8 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M1-1 M1-2 M1-3 M1-4 MI-5 MI-6 M1-7 Mi-8 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M1-1 M1-2 Mi-3 MI-4 MI-5 M1-6 MI-7 Mi-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 Mi-1 M1-2 MI-3 M1-4 MI-5 MI-6 M1-7 M1-8 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 Mi-1 M1-2 M1-3 MI-4 MI-5 MI-6 M1-7 Mi-8 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M1-1 M1-2 M1-3 MI-4 MI-5 M1-6 M1-7 Mi-8 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 M12-7 The vaccine disclosed herein may comprise about 10 serotype-specific peptides, each peptide corresponding to one of the 10 most prevalent serotypes in the U.S., thus 5 making it expected to immunize against approximately 65% of GAS disease in the U.S. More specifically, this vaccine can comprise combinations of 10 peptides wherein one peptide comes from each of the M1, M3, M28, M12, M4, M 11, M89, st2967, M77/27L, M6 peptides from Table 1. As demonstrated above, the combinations can be generated and tested according to the procedures described in this application to 2621679_1 (GHMatters) P51243.AU.1 2/05/11 - 23 determine those which are effective. It is contemplated that the vaccine may comprise about 30 serotype-specific peptides of the 30 most prevalent serotypes, thus making it expected to immunize against approximately 95% of GAS disease in the U.S. More specifically, this vaccine can comprise combinations of 30 peptides wherein one 5 peptide comes from each of the 30 most prevalent serotypes. As demonstrated above, the combinations can be generated and tested according to the procedures described in this application to determine those which are effective. It is also contemplated that the vaccine can comprise at least one serotype-specific peptide from any identified serotype of GAS. A vaccine covering approximately 60% of GAS disease would be 10 expected to be commercially viable. Figure 1 shows the most prevalent serotypes in the U.S. currently from which the serotype-specific peptides could be chosen to target. Similar data from any targeted population could be used to tailor the vaccine for the prevalent serotypes and a given percentage of disease. This strategy towards a safe and effective vaccine against GAS offers the advantage of being easily modified to fit 15 the needs of a particular region according to the predominant M types located there. As indicated above, based on the current epidemiological data, similar serotype-specific peptides would be expected to be effective in vaccines or compositions in the U.S., Italy, Mexico and Argentina, for example. The 20 epidemiological data of Malaysia, India, New Guinea, Nepal and Egypt indicate that vaccines or compositions tailored to these areas may require a different subset of GAS serotype-specific peptides. Based on the teaching herein, such a vaccine is easily within the grasp of the skilled person. 25 Another strategy for designing a vaccine would be to make it selective for specific GAS illnesses, as all GAS do not cause the same illnesses. For example, the most severe GAS diseases are often considered to be necrotizing fasciitis and toxic shock syndrome which are most frequently caused by M1 and M3. Thus, selecting immunogenic molecules specific to these serotypes would tailor the vaccine to this 30 strategy. More specifically, the combinations could be, for example, Mi-1 M1-2 M1-3 M1-4 M1-5 M1-6 M1-7 M1-8 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 M3-1 MI-1 M1-2 M1-3 M1-4 M1-5 M1-6 M1-7 M1-8 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 M3-2 Mi-1 M1-2 M1-3 M1-4 M1-5 M1-6 M1-7 M1-8 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 M3-3 Mi-1 M1-2 M1-3 M1-4 M1-5 M1-6 M1-7 M1-8 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 M3-4 2621679_1 (GHMatters) P51243.AU.1 2/05/11 -24 M1-1 M1-2 M1-3 M1-4 M1-5 M1-6 M1-7 M1-8 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M3-5 M1-1 M1-2 M1-3 M1-4 M1-5 M1-6 M1-7 M1-8 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M3-6 M1-1 M1-2 M1-3 M1-4 M1-5 M1-6 M1-7 M1-8 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M3-7 M1-1 M1-2 M1-3 M1-4 M1-5 M1-6 M1-7 M1-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M3-8 M1-1 M1-2 M1-3 M1-4 M1-5 M1-6 M1-7 M1-8 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M3-9 M1-1 M1-2 M1-3 M1-4 M1-5 M1-6 M1-7 M1-8 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M3-10 M1-1 M1-2 M1-3 M1-4 M1-5 M1-6 M1-7 M1-8 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 M3-11 The peptides, compositions, vaccines or antibodies (discussed below) of the present disclosure may be administered by any mode of administration capable of delivering a desired dosage to a desired location for a desired biological effect which 5 are known to those of ordinary skill in the art. One of ordinary skill would be able to determine these dosages and routes by routine experimentation. Routes or modes include, for example, orally, parenterally (e.g., intravenously, by intramuscular injection, by intraperitoneal injection), or the like, although subcutaneous administration is preferred. Though the vaccine is envisioned as an injectable, such as subcutaneous or 10 intramuscularly, the vaccine may be formulated in such a way as to render it mucosally deliverable without the peptides being broken down before providing systemic or mucosal immunity, such as, orally, inhalationally, intranasally, or rectally. The amount of active compound administered will, of course, be dependent, for example, on the subject being treated, the subject's weight, the manner of administration and the 15 judgment of the prescribing physician. Immunogenic amounts can be determined by standard procedures. Examples of other peptide vaccines are known in the art. Dosages are expected to be in similar ranges. Depending on the intended mode of administration, the compositions or 20 vaccines may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage form suitable for single administration of a precise dosage. The compositions or vaccines may include, as noted above, an effective amount of the selected immunogens in combination with a pharmaceutically 25 acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc. 26216791 (GHMatters) P51243.AU.1 2)05/11 - 25 A more recently revised approach for parental administration involves use of a slow release or sustained release system, such that a constant level of dosage is maintained. See, e.g., U.S. Patent No. 3,710,795, which is incorporated by reference herein. A system using slow release or sustained release may be used with oral 5 administration as well. The vaccine or composition may be administered in liposomes, encapsulated, or otherwise protected or formulated for slower or sustained release. A subject can be inoculated to generate an active immune response to the presence of the immunogenic composition which can later protect the subject from the 10 organism. A passive immune response may be accomplished by any method known in the art. Kits using the peptides or antibodies disclosed herein may be made. A kit comprises packaging and the antibodies or peptides. A kit may further comprise a solid 15 phase or substrate to which the antibodies or peptides may be attached. Antibodies Antibodies are also within the scope of the present disclosure. For example, isolated antibodies which selectively bind with the peptides of the present disclosure 20 are envisaged. These antibodies can be used, for example, in diagnosis, treatment, or vaccination techniques. The antibodies can be monoclonal or specific antibodies. The antibodies can be opsonic antibodies or anti-attachment antibodies. The antibodies are made and isolated by methods well known in the art. Modified antibodies, fragments and humanized antibodies are also within the scope of this disclosure. It is well known 25 in the art how to make and use modified antibodies, fragments or humanized antibodies. Methods and Uses The peptides, compositions, vaccines, and antibodies of the present disclosure 30 may be used in a variety of applications. For example, preventative/prophylactic, therapeutic, or diagnostic methods; affinity chromatography for separating/purifying antibodies or antigens; active/passive immunotherapy; and use of antibodies generated in passive immunotherapy. 35 An example of a method of preventing GAS infection comprises administering a prophylactically effective amount of vaccine, or of an anti-idotype antibody to the peptides of the present disclosure, to a subject. Also, the antibodies against the 26216791 (GHMatters) P51243.AU.1 2105111 - 26 peptides of the present disclosure may be administered in a prophylactically effective amount. An example of a method of treating a GAS infection comprises administering a 5 therapeutically effective amount of antibodies of the present disclosure to a subject. An example of a diagnostic method is determining the serotype of GAS organism responsible for an infection by contacting a sample with multiple serotype specific antibodies of the present disclosure and determining which of these serotype 10 specific antibodies are actually bound with the infecting organism. An example of another diagnostic method is contacting a sample with multiple serotype-specific peptides of the present disclosure and determining which serotype-specific peptides are actually bound with antibodies in the sample. 15 A method of measuring the amount of GAS organism in a sample comprising contacting a sample with antibodies of the present disclosure and measuring the amount of immunocomplexes formed. Affinity chromatography is frequently used for separating and/or purifying 20 antibodies or antigens. By binding the corresponding antibody or antigen to a substrate, a sample can be passed through a column containing the immunoadsorbent and then the column eluted to collect the isolated corresponding antigen or antibody. More specifically, the peptides of the present disclosure can be bound on a column to purify anti-GAS antibodies. Likewise, anti-GAS antibodies generated in accordance 25 with the present disclosure can be bound to a column and used to purify GAS from a sample. Immunotherapy is another use for the peptides, compositions, vaccines or antibodies of the present disclosure. As known in the art, active immunotherapy is 30 achieved by activating a subject's own immune system. By administering the peptides, compositions or vaccines of the present disclosure, an active immune response may be elicited. As known in the art, passive immunotherapy is achieved by supplementing a 35 subject's immune system with agents such as antibodies. By administering the antibodies of the present disclosure, a passive immune response may be elicited. 26216791 (GHMatters) P51243AU.1 2105/11 - 27 The method for tailoring vaccines comprises a) identifying a population of recipients for the vaccine; b) gathering prevalence data on serotypes of the targeted organism from a sample within that population of recipients; c) choosing a set of the most prevalent serotypes from the gathered data; d) identifying proteins from the 5 chosen serotypes responsible for evading opsonophagocytosis; e) identifying small peptides within the identified proteins which protect for the chosen serotypes; f) synthesizing the identified peptides; g) formulating a vaccine comprising the peptides identified in step e). Specifically, the small peptides may be those of about 20-25 amino acids and protection may be by elicitation of opsonic or anti-attachment 10 antibodies. Other uses for or variations of the above methods using the above peptides, compositions, vaccines or antibodies may be readily apparent to one of ordinary skill in the art. 15 The approach of employing a mixture of defined synthetic N terminal M protein segments protecting against prevalent U.S. Group A streptococcal (GAS) strains will favorably compare against any of the prior art approaches. The present approach has found excellent immunogenicity and type-specific opsonic antibody titers with the 20 peptides assessed. Animal studies have indicated that individual peptides protect in a type-specific manner not only against systemic infection, but against nasopharyngeal carriage of GAS. Many N terminal M protein segments have already been demonstrated to not evoke antibodies cross-reactive with human tissues. There is no evidence that chemically linking the current peptides to carriers or backbones will 25 increase the risk of undesirable cross reactions. The methodology can be proven for each of the most common M types found in U.S. invasive disease isolates. The strategy can be expanded to less frequently occurring GAS types. This allows the vaccine to be quickly and precisely adapted to changes in individual strain frequencies in a given geographic area or demographic population by addition or deletion of 30 individual peptide components. 2621679_1 (GHMatters) P51243AU.1 2/05/11 28 EXAMPLES Experimental The following examples are put forth so as to provide those of ordinary skill in 5 the art with a complete disclosure and description of how the compounds, compositions, articles, devices, and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.) but some 10 errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in *C or is at ambient temperature, and pressure is at or near atmospheric. Materials and methods 15 A CDC surveillance system used a rapid gene-based M subtyping system to gather epidemiological data and showed that the 30 most prevalent invasive M types account for approximately 95% of the total invasive isolates in the U.S. Peptide synthesis and purification 20 Synthetic peptides (approximately 20-25-mers), representing epitopes of the most prevalent GAS M types were synthesized. Their sequences were derived from the M protein N-terminal region that confers type-specific immunity. Peptides were synthesized on a Model ACT396 Omega multiple peptide 25 synthesizer (Advanced Chemtech, Louisville, KY) by Fmoc-chemistry using a HOBT/DIC strategy with double couplings. Matrix-assisted laser desorption/ionization, time-of-flight mass spectroscopy (MALDI-TOF MS) (Bruker REFLEX, Billerica, MA) was utilized to determine the mass to charge (m/z) of the crude peptides. 30 Abbreviations: Fmoc (9-fluorenylmethyloxycarbonyl) HOBT (1 -hydroxybenzotriazole) DIC (Diisopropylcarbodiimide) 29 Enzyme-linked immunosorbent assay (ELISA) Overlapping peptides representing each M type were assessed for their immunogenicity using ELISA and dot-immunoblot. 5 Levels of anti-M protein antibodies in mouse sera were determined by an enzyme-linked immunosorbent assay (ELISA) using either synthetic peptides or whole M protein as antigen. Microtiter plates (DYNEX Imulon 2 HB) were coated with 10 pg/ml antigen in 10 mM phosphate-buffered saline (PBS) at 4*C overnight. Plates were rinsed three times with wash buffer (0.05% Tween 20 in 10 mM PBS, pH 7.2) 10 and blocked with 1% BSA in PBS for one hour at 37*C. The appropriate test sera were applied at a starting dilution of 1:1000 and serially diluted two fold down the plate in PBS. Plates were incubated at 37 C for 30 minutes and subsequently rinsed three times. Goat anti-rabbit or goat anti-mouse Ig-peroxidase conjugate diluted 1:10,000 in PBS was added to all wells and incubated for two hours at 37"C. Plates were rinsed 15 three times with wash buffer and freshly prepared TMB peroxidase (Kirkegaard and Perry Laboratories) was added. Reactions were quenched with 0.18 M H 2 S0 4 after 30 minutes at room temperature and OD 450 was measured with a Labsystems Multiskan plate reader using Ascent software. ELISA titers are expressed as the reciprocal of the last dilution which gave a reading OD 4 50 > 0.10. 20 Immunization Mice (6 week old female Swiss Webster, Harley-Sprague) were immunized subcutaneously (s.c.) with either the peptide in alum or alum alone for control groups. Peptides were rotated in the alum mixture for 2 hours at 4"C and stored at 4*C 25 overnight prior to use. Initial injections (100 yul) consisted of 50 psg peptide in alum (25 pg for M3-2 peptide) with identical booster injections given at 2 and 4 weeks (except for the M3-2 peptide which was only given as an initial dose and single booster at 2 weeks). 30 Opsonophagocytosis Opsonophagocytosis assays were performed as previously described in Lancefield, R.C., Persistence of type-specific antibodies in man following infection with group A streptococci, 1959, J. Immunol., 89:307. Briefly, diluted serum (50 pl) was added to mid-log phase GAS (103 CFU) in Todd-Hewitt broth (50 p2l) and whole, 35 heparinized blood (500 pl) from a nonopsonic human donor. Mixtures were briefly vortexed and placed at 37*C in a shaker for 3 hours. Dilutions were then plated on 30 trypticase soy agar plates (5% sheep blood) to quantitate viable organisms. The % killing is expressed as [(CFU control-CFU test) / CFU control] X 100. NP challenge 5 Mice were challenged intranasally one week after the final booster injection was administered. Prior to being challenged, mice were anesthetized with a ketamine/xylazine mixture. Mice were then given 10 4 -10 5 CFU (10 pl) of streptococci intranasally via a microliter pipette. They were sacrificed 24 hours after the challenge and the nasopharyngeal passages were washed with approximately 100 jl 10 physiological saline which was collected and immediately placed on ice. Dilutions of the wash were then plated on trypticase soy agar plates (5% sheep blood) and incubated at 37 *C for 18 hours to quantitate viable organisms. Nasopharyngeal colonization in immunized mice was compared to non-immunized controls. Statistical analysis of the NP data was accomplished using the t-test and rank sum test. 15 Detection of heart cross-reactive antibodies Mouse sera were screened for heart cross-reactive antibodies with an indirect immunofluorescence assay (IFA). Glass slides containing formaline-fixed human heart tissue were deparaffinized before use and stored in dH 2 0. Slides were air-dried 10 20 minutes and incubated in a moist chamber with 1:500 mouse test sera at room temperature for 30 minutes. Slides were rinsed and soaked in PBS for 5 minutes. Slides were then incubated in a moist chamber with 1:500 goat anti-mouse FITC labeled globulin at room temperature for 30 minutes. Slides were washed as described previously and allowed to air-dry. One drop of mounting fluid (DAKO) was applied to 25 each slide followed by a glass cover slip (Corning 24 x 40 mm). Slides were immediately examined under a fluorescent microscope. The positive control was a 1:500 mouse anticlonal antibody to human HLA (Caltag). Example 1 30 Peptide recognition by anti M-protein rabbit sera The immunoreactivity of several synthetic peptides was determined by ELISA using rabbit sera prepared against whole M protein. The synthetic peptides are representative of relatively small portions of the M protein N-terminus; therefore, it 35 was advantageous to determine if the epitopes contained within particular peptides were immunoreactive with sera prepared against whole M protein. It was shown that 31 the whole anti-M protein rabbit sera of the respective serotypes could bind to each of the synthetic peptides within that serotype. However, some peptides were more highly immunoreactive than others, thus being better suited for use in the animal studies. The peptides showing the highest reactivity in each serotype group tested were M1 -4, M3-2 5 and M12-1. This indicated that immunoreactive epitopes were contained within the amino acid sequences of the synthetic peptides. The immunoreactivity of peptides with SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, 10 SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:3 1, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, 15 SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, 20 SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, 25 SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ 30 ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO: 124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID 35 NO:134, SEQ IDNO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ IDNO:138 are confirmed by ELISA using rabbit sera prepared against whole M protein.

32 Example 2 Immunogenicity of synthetic peptides in Swiss Webster Mice 5 Studies were then carried out in vivo in a mouse model to determine the ability of the tested synthetic peptides to protect against GAS challenge and to evaluate their immunogenicity as a single MAP formulation. Mice were immunized s.c. with selected peptides using aluminum hydroxide or 10 aluminum phosphate as an adjuvant. Serology results indicated that aluminum hydroxide elicited higher antibody levels and, therefore, it was used for all subsequent immunizations. ELISA indicated that antibodies were elicited to the M type peptides. TABLE 2. ELISA results determining elicitation of antibodies. 15 Peptide ELISA MI-4 no M1-2 no MI-3 yes M3-1 yes M3-2 yes M3-4 no M12-1 yes M12-2 yes (weak) M12-3 no Five of the nine synthetic peptides shown in Table 2 were able to elicit an antibody response, with each of the three serotypes under investigation being represented by at least one immunogenic peptide. The titers of the immunogenic 20 peptides were as follows: 33 TABLE 3. Titers of the immunogenic peptides in immunized mice. Peptide Titer M1-3 1:16,000 M3-1 1:8,000 M3-2 1:160,000 M12-1 1:160,000 M12-2 1:1000 Mice are immunized s.c. with peptides and various combinations of peptides 5 with SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID 10 NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID 15 NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID 20 NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID 25 NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO: 110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, 34 SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138. 5 ELISA is used to confirm antibody elicitation to at least some of the peptides and peptide combinations. Titers are determined for the peptides and combinations of peptides. Example 3 Opsonophagocytosis 10 The mouse sera that were shown to contain anti-M antibodies by the ELISA assay were then tested for functional activity with the in vitro opsonophagocytosis assay (Lancefield 1959), Table 4. Each of the sera tested positive in the assay and was able to reduce the amount of viable bacteria relative to controls. The values for the 15 reduction of bacteria in the opsonophagocytosis assays were as shown in Table 5. TABLE 4. Sera results for opsonophagocytosis assay. Peptide Opsono (in vitro) M1-4 nd M1-2 nd M1-3 yes M3-1 yes M3-2 yes M3-4 nd M12-1 yes M12-2 nd M12-3 nd 35 TABLE 5. Percentage reduction of viable GAS bacteria. Peptide Reduction M1-3 50% M3-1 80-90% M3-2 60-80% M12-1 70-80% It is interesting to note that within the M3 serotype, while the M3-1 peptide induced an 5 antibody response that was more than a magnitude lower than that of the M3-2 peptide, it was able to opsonophagocytize bacteria more effectively. Mouse sera is tested that is shown to contain anti-M antibodies from the peptides and combinations of peptides selected from SEQ ID NO:1, SEQ ID NO:2, 10 SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID 15 NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID 20 NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID 25 NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO: 101, SEQ ID NO:102, SEQ ID 30 NO:103, SEQ IDNO:104, SEQ IDNO:105, SEQ IDNO:106, SEQ IDNO:107, SEQ 36 ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, 5 SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO: 136, SEQ ID NO:137, SEQ ID NO:138 for functional activity with an in vitro opsonophagocytosis assay. The sera test positive in the assay and are able to reduce the amount of viable bacteria relative to controls. 10 Example 4 Nasopharyngeal Colonization Challenge Nasopharyngeal (NP) colonization challenge experiments were performed on 15 mice vaccinated (s.c.) with either M3-1 or M3-2 peptide in alum in comparison to control animals which received alum only. The nasopharyngeal colonization challenge was performed by doing a nasal wash 24 hours after challenge. The subjects were administered 104 CFUs 1 week after final boost. Dilutions of the wash were plated. Both peptides were able to induce an effective in vivo immune response that reduced 20 colonization in the vaccinated group relative to the unvaccinated group. TABLE 6. Reduction of nasopharyngeal colonization in vaccinated mice relative to control mice. Peptide Reduction of colonization P M3-1 87% P=0.010 M3-2 67% P=0.029 25 The M3-1 peptide reduced NP colonization by 87% (P<0.010), while the M3-2 peptide was able to reduce NP colonization by 67% (P<0.029) relative to the control group. No deaths were recorded in any group. To our knowledge this is the first example of in vivo reduction of nasopharyngeal colonization of GAS bacteria by immunization with a 30 type-specific synthetic peptide. NP colonization challenges are performed on mice vaccinated s.c. with the peptides and peptide combinations selected from SEQ ID NO:1, SEQ ID NO:2, SEQ 37 ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO: 11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID 5 NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:3 1, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID 10 NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID 15 NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID 20 NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO: 112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ 25 ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO: 137, and SEQ ID NO: 138. Peptides and peptide combinations are confirmed to induce an effective in vivo immune response that reduced colonization in the 30 vaccinated group relative to the unvaccinated group. No deaths are reported in any group. Example 5 Cross-Type Protection by Peptides 35 38 Some of the peptides tested in the previous examples were tested for cross-type protection using the methods described above. Table 7 shows in vitro data on reduction in bacteria versus a control. The peptide tested and serotype against which it was tested is indicated. This example clearly shows that peptides M3-1 and M3-2 were 5 able to significantly reduce M43 type bacteria in addition to M3 type bacteria. TABLE 7. Functional antibody bactericidal activity in vitro showing cross protection against heterologous M type. Peptide GAS M type used in % CFU assay reduction M1-3 M1 80-95% M3-1 M3 70-90% M3-2 M3 90-95% M12-1 M12 70-80% M3-1 M43 80-90% M3-2 M43 60-80% 10 Some of the peptides were tested for reduction of colonization of GAS in mice. The second line of data shows mice immunized with peptides M1-3, M3-2 and M12-1. The peptides were administered together but were not chemically combined in any way. The third line of data shows mice that were inoculated with M3-2. Some of the 15 mice were colonized by M3, and some of the mice were colonized by M43. The % CFU reduction is the reduction overall for the mice which received M3-2. This again demonstrates that M3-2 was capable in vivo of cross-type protection. TABLE 8. Reduction of colonization in mice. 20 Peptides Colonizing GAS M type % CFU reduction (P value) M1-3 M1 90% (P<0.10) M1-3, M3-2, M12-1 M1 74% (P<0.25) M3-2 M3 or M43 67% (P<0.30) The cross-type protection is confirmed for peptides and peptide combinations selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID 39 NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ 1D NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, 5 SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, 10 SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, 15 SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, 20 SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ 25 ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, and SEQ ID NO: 138. Reductions in bacteria are shown in vitro and in vivo. 30 Example 6 Detection of Heart Cross-Reactive Antibodies Mouse immune sera that contained functional antibody were examined for the presence of heart cross-reactive antibodies with an IFA. The mouse sera were tested in 35 parallel with a positive control, mouse monoclonal antibody to human leukocyte 40 antigen (HLA). None of the anti-M peptide sera from immunized mice reacted with the heart tissue. Throughout this application, various publications are referenced. The 5 disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. It will be apparent to those skilled in the art that various modifications and 10 variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the 15 following claims. The entire disclosure in the complete specification of our Australian Patent Application No. 2002305645 is by this cross-reference incorporated into the present specification.

Claims (21)

1. A composition comprising at least one polypeptide comprising the amino acid sequence according to any one of SEQ ID NOs:1, 3 and 14, wherein the polypeptide is 5 capable of eliciting an immune response to a serotype of Group A Streptococcus (GAS) and does not elicit tissue cross-reactive antibodies.

2. The composition of claim 1, wherein the composition is a mixture of polypeptides. 10

3. The composition of claim 2, wherein the mixture of polypeptides comprises one or more of the Group A Streptococcus (GAS) M-type peptides selected from each of the 25 serotypes listed in Table 1. 15

4. The composition of claim 3, wherein the mixture of polypeptides comprises at least one peptide selected from serotypes M1, M2, M3, M4, M 11, M12, M22, M28, M77, M89, st2967, M6, M82, M43, M75, M33, M92, M5, M94, M73, M18, M58, M59, M101, and M41. 20

5. The composition of claim 2, wherein the mixture of polypeptides comprises one or more peptides selected from 10 of serotypes listed in Table 1.

6. The composition of claim 5, wherein the mixture of polypeptides comprises at least one peptide selected from serotypes M1, M3, M28, M12, M4, M11, M89, st2967, 25 M77, and M6.

7. The composition of claim 1, wherein the one or more peptides are linked to a backbone. 30

8. The composition of claim 1, further comprising a pharmaceutically acceptable vehicle or carrier, or additional immune-stimulatory molecules.

9. The composition of claim 8, wherein the additional immune-stimulatory molecules comprise GAS-based peptides; adjuvants; or non-GAS 35 vaccines/immunogens selected from the group consisting of Hemophilus influenza, pertussis, N. Meningitidis, pneumococcus, and Influenzae. 26216791 (GHMatters) P51243.AU.1 2/05/11 - 42

10. The composition of claim 1, wherein the at least one polypeptide consists of the amino acid sequence of any one of SEQ ID NOs:1, 3 and 14.

11. An immunogenic composition for eliciting a protective immune response to 5 Group A Streptococcus comprising an immunogenic amount of the composition according to claim 1.

12. The immunogenic composition of claim 11, wherein the immunogenic composition is capable of eliciting functional opsonic antibodies and does not contain 10 epitopes that cross-react with tissues, or is effective in decreasing the nasopharyngeal reservoir of GAS when administered.

13. A method for inducing an immune response against multiple serotypes of Group A Streptococcus comprising administering an immunogenic amount of the 15 immunogenic composition of claim 1 to a subject.

14. The method of claim 13, wherein the administration is via injection or a mucosal delivery method. 20

15. The method of claim 13, wherein the immune response is induction of opsonic antibodies and/or anti-attachment antibodies.

16. The method of claim 15, wherein the serotypes are selected from emm1, emm2, emm3, emm4, emm11, emml2, emm22, emm28, emm77, emm89, st2967, 25 emm6, emm82, emm43, emm75, emm33, emm92, emm5, emm94, emm73, emm18, emm58, emm59, emm101, and emm4l.

17. An isolated polypeptide comprising the amino acid sequence according to any one of SEQ ID NOs:1, 3 and 14 wherein the polypeptide is capable of eliciting an 30 immune response to a serotype of GAS and does not elicit tissue cross-reactive antibodies.

18. The composition of claim 1 or the polypeptide of claim 17, wherein the polypeptide is included in a chimeric fusion protein. 35

19. The composition or polypeptide of claim 18, wherein the chimeric fusion protein comprises an amino acid sequence of one or more heterologous Group A 26216791 (GHMatters) P51243.AU.1 2/05/11 - 43 Streptococcus (GAS) M-type peptides.

20. The isolated polypeptide of claim 17, wherein the polypeptide consists of the amino acid sequence of any one of SEQ ID NOs:1, 3 and 14. 5

21. The composition of claim 1 or claim 11, method of claim 13, or isolated polypeptide of claim 17, substantially as hereinbefore described with reference to the accompanying examples and/or figures. 26216791 (GHMatters) P51243.AU.1 2/05/11